FDA Set to Outline ‘Major Steps’ Toward Real-Time Clinical Trials

On Tuesday (4/28), FDA is expected to detail a significant shift in how clinical trials are conducted and regulated, announcing “major steps to implement real-time clinical trials.” According to agency communications and recent public statements, the move signals the clearest indication yet that FDA is preparing to operationalize a long-developing concept: clinical studies in which patient data are monitored continuously and regulatory decisions can evolve in near real time.

Traditional clinical trials proceed in discrete phases and rely on periodic data analysis after predefined milestones. By contrast, FDA’s emerging framework would allow regulators to access trial data as it is generated — potentially through cloud-based systems — enabling ongoing safety and efficacy assessments.

Senior agency officials have recently indicated that the FDA is “very close” to launching a pilot program built around a “real-time continuous trial” model. That approach could allow studies to be modified midstream, halted early for strong results, or adjusted in response to safety signals without waiting for formal phase transitions.

The methodology is expected to rely heavily on adaptive trial designs and statistical approaches such as Bayesian analysis, which support continuous updating of evidence as new data becomes available.

While the upcoming announcement may mark a formal inflection point, the groundwork has been laid over several years through a series of regulatory and technological initiatives. For example, FDA has expanded its use of real-world evidence, drawing on data from electronic health records, insurance claims, and patient registries to complement or, in some cases, substitute for traditional trial data. At the same time, the agency has encouraged the adoption of digital health technologies — including wearable sensors and remote monitoring tools — that enable continuous data collection outside clinical sites.

Guidance issued by the agency has also promoted embedding randomized trials within routine clinical care, reducing the separation between research and treatment. More recently, FDA has shown greater flexibility in approval standards, including openness to single pivotal trials and streamlined development programs.

Taken together, these changes form the infrastructure for real-time trials: continuous data capture, integration with healthcare systems, and regulatory frameworks capable of acting on evolving evidence.

If implemented broadly, real-time clinical trials could significantly compress drug development timelines and reduce costs, while also allowing patients earlier access to promising therapies. For pharmaceutical companies, the shift could require substantial investment in data infrastructure, analytics, and trial design capabilities. It could also alter competitive dynamics, favoring firms that can rapidly generate and interpret high-quality data.

At the same time, the model raises complex regulatory and ethical questions, including how to ensure data integrity, manage patient privacy, and maintain rigorous evidentiary standards in a continuously evolving trial environment.

Details of the FDA’s planned initiative —  whether it will begin as a limited pilot or a broader program — are expected to be unveiled at a press conference on Tuesday.